Integrated BioPharma Inc lost $0.09 per diluted share in fiscal year 2026. This represents a decrease of 400.0% from the prior fiscal year. The table below carries 15 fiscal years, from 2012 to 2026, and the quarters Integrated BioPharma Inc has filed alongside them.
FY2026 annual
EPS (Diluted)-$0.09
YoY-400.0%
Source SEC Filings (10-K/10-Q)Latest period FY2026, ended Jun 30, 2026ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
INBP EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
Integrated BioPharma Inc lost $0.09 per diluted share in fiscal year 2026.
Integrated BioPharma Inc (INBP) diluted earnings per share fell by 400.0% year over year, from $0.03 to -$0.09 in fiscal year 2026.
Across the 15 fiscal years this page covers, Integrated BioPharma Inc (INBP) diluted earnings per share went from -$0.13 in fiscal year 2012 to -$0.09 in fiscal year 2026.
Integrated BioPharma Inc (INBP) reported -$0.04 in diluted earnings per share in Q4 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Integrated BioPharma Inc (INBP) reported on that line in every period on record.
